A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects.

Trial Profile

A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Mar 2010

At a glance

  • Drugs Latrepirdine; Warfarin
  • Indications Alzheimer's disease; Cardiovascular disorders; Huntington's disease
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 17 Mar 2010 Results presented at the 111th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 20 Feb 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 27 Jan 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top